Events Supposedly Attributed to Vaccine or Immunization of the AstraZeneca Vaccine: a Case Study
Published: 2023-07-06
Page: 105-109
Issue: 2023 - Volume 6 [Issue 1]
Ruvalcaba Ledezma Jesús Carlos *
Department of Medicine and Master in Public Health, Hidalgo State University, Pachuca City, Hidalgo (UAEH), Mexico.
Josefina Reynoso Vazquez
Department of Pharmacy and Masters in Public Health, Hidalgo State University, Pachuca City, Hidalgo (UAEH), Mexico.
Claudia Teresa Solano Pérez
Department of Medicine, Hidalgo State University, Pachuca City, Hidalgo (UAEH), Mexico.
Ana Erandi Montiel Hernández
Autonomous University of Nuevo León (UANL), México.
Miguel Bosco Palau Cantu
National Autonomous University of Mexico, Mexico.
María del Consuelo Cabrera Morales
Department of Medicine and Master in Public Health, Hidalgo State University, Pachuca City, Hidalgo (UAEH), Mexico.
*Author to whom correspondence should be addressed.
Abstract
A case of Events Supposedly Attributed to Vaccination or Immunization (ESAVI) due to the application of the AstraZeneca vaccine was presented on December 14th of 2021, with 14 days from beginning to resolution. It was treated with 2 administrations of Dexamethasone of 8 mg, one every 24 hours and Fexofenadine 120 mg 1 tablet every 12 hours for 7 days, stating being discharged on Tuesday 28th with vital signs within normal parameters, although wheals were slightly visible, they gradually disappeared.
Keywords: AstraZeneca, attributable, ESAVI, vaccine
How to Cite
Downloads
References
Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing - An overview. Vaccinate. 2017;35(33):4064-71.
Diaz QJA. Vaccines against COVID-19 and appearance of variants of SARS-CoV-2. Reflecting on the case of Mexico. Medical Gazette of Mexico. 2021;157(2): 125-126. Available: https://doi.org/10.24875/gmm.m21000499
Arias CD, Postigo ZJ, Chumacero CJ. World scientific production on the vaccine against Covid-19: analysis of the period 2020-2021. Venezuelan Archives of Pharmacology and Therapeutics, 2021; 40(4):396-405.
Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969-73.
World Health Organization [Internet]. Coronavirus disease (COVID-19): Vaccines. Available:https://www.who.int/es/news-room/q-a-detail/coronavirus-disease-(covid-19)vaccines?adgroupsurvey={adgroupsurvey}&gclid=EAIaIQobChMI-uGQifrL7QIVgaGGCh3MGgUKEAAYASAAEgLtcfD_BwE
Everything you need to know about the Oxford/AstraZeneca ChAdOx1-S (recombinant) COVID-19 vaccine. Available:https://www.who.int/es/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know
SARS-CoV-2 vaccine file, AZD1222 vaccine- AstraZeneca Laboratory. disease prevention and control division. Undersecretary of Public Health. Ministry of Health, Government of Chile; 2021. Available:https://www.minsal.cl/wp-content/uploads/2021/04/FICHA-ASTRAZENECA.pdf
AZD1222 Vaccine Application Technical Guide. AstraZeneca, against the SARS-CoV-2 virus; 2022. Available:https://coonavirus.gob.mx/wp-content/uploads/2021/03/GTApp_AstraZeneca_050321.pdf
World Health Organization. Recommendation for an emergency use listing of AZD1222 submitted by AstraZeneca AB and manufactured by SK Bioscience Co Ltd; 2021.
Available:https://extranet.who.int/pqweb/sites/default/files/documents/AZD1222_TAG_REPORT_EUL%20vaccine_FEB2021_v2 .pdf
European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. 20 April 2021, from the European Medicines Agency; 2021. Available:https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possiblelink-very-rare-cases-unusual -blood-clots-low-blood
Guzman PMG, Saeb LM. Delayed immediate skin reactions to COVID-19 vaccines: series of five cases. Acta Med. 2021;19(Suppl:1):84-90. doi:10.35366/101035
Gladys Turpo. University of Oxford. AstraZeneca. Available:https://www.dge.gob.pe/portalnuevo/wp-content/uploads/2022/10/Vigilancia-ESAVI-Severo.pdf
Vaxzevria vaccine. Vaxzevria1 (COVID-19 vaccine (ChAdOx1-S [recombinant])) General information on Vaxzevria and why it is authorized for use in the EU European Medicines Agency; 2021. Available:https://www.ema.europa.eu/en/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_es.pdf
WHO Summary of Product Characteristics; 2021. Available:https://www.digemid.minsa.gob.pe/UpLoad/UpLoaded/PDF/COVID19/VACUNAS/CHADOX1_CATALENT/FICHA_TECNICA.PDF
Vaccine astrazeneca University of Oxford; 2021. Available:https://www.minsal.cl/wp-content/uploads/2021/06/Recomendaciones-CAVEI-uso-vacuna-COVID-19-de-AstraZeneca -Oxford.pdf